^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MIR200B (MicroRNA 200b)

    i
    Other names: mir-200b, MicroRNA 200b, Hsa-MiR-200b-5p, Hsa-MiR-200b-3p, Hsa-Mir-200b, MIRN200B, MIR200B
    3d
    Role and underlying mechanisms of miR‑200 family in breast cancer (Review). (PubMed, Int J Oncol)
    Furthermore, members of the miR‑200 family have potential as diagnostic and prognostic biomarkers and are closely linked to chemotherapy resistance. The present review aims to provide novel insights and a theoretical foundation for the diagnosis, treatment, and deeper investigation of BC by comprehensively examining the functional mechanisms of the miR‑200.
    Review • Journal
    |
    MIR200B (MicroRNA 200b) • MIR200C (MicroRNA 200c) • MIR200A (MicroRNA 200a) • MIR141 (MicroRNA 141) • MIR200 (MicroRNA 200)
    1m
    Differentially Expressed Genes Associated with the Development of Cervical Cancer. (PubMed, Int J Mol Sci)
    The publicly available microarray datasets, including GSE39001, GSE9750, GSE7803, GSE6791, GSE63514, and GSE52903 in combination with bioinformatics database predictions, were used to identify differential expression genes, potential biomarkers, and therapeutic targets for cervical cancer; additionally, we undertook bioinformatic analysis to determine gene ontology and possible miRNA targets related to our DEGs...Interestingly, hub proteins KIF4A, NUSAP1, BUB1B, CEP55, DLGAP5, NCAPG, CDK1, MELK, KIF11, and KIF20A were found to be potentially regulated by several miRNAs, including miR-107, miR-124-3p, miR-147a, miR-16-5p, miR-34a-5p, miR-34c-5p, miR-126-3p, miR-10b-5p, miR-23b-3p, miR-200b-3p, miR-138-5p, miR-203a-3p, miR-214-3p, and let-7b-5p. The relationship between these genes highlights their potential as candidate biomarkers for further research in treatment, diagnosis, and prognosis.
    Journal
    |
    TP53 (Tumor protein P53) • TOP2A (DNA topoisomerase 2-alpha) • RAD51 (RAD51 Homolog A) • MIR200B (MicroRNA 200b) • MIR34A (MicroRNA 34a-5p) • RAD51AP1 (RAD51 Associated Protein 1) • NUSAP1 (Nucleolar and Spindle Associated Protein 1) • ELF3 (E74 Like ETS Transcription Factor 3) • FOXM1 (Forkhead Box M1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • MIR126 (MicroRNA 126) • MIR16 (MicroRNA 16) • MIR23b (MicroRNA 23b) • NCAPG (Non-SMC Condensin I Complex Subunit G) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CEP55 (Centrosomal Protein 55) • CXCL14 (C-X-C Motif Chemokine Ligand 14) • E2F1 (E2F transcription factor 1) • KIF20A (Kinesin Family Member 20A) • KIF4A (Kinesin Family Member 4A) • MCM2 (Minichromosome maintenance complex component 2) • MCM5 (Minichromosome Maintenance Complex Component 5) • MIR10B (MicroRNA 10b) • MIR138 (MicroRNA 138) • MIR203A (MicroRNA 203a) • MIR214 (MicroRNA 214) • MIRLET7B (MicroRNA Let-7b) • RELA (RELA Proto-Oncogene) • RFC4 (Replication Factor C Subunit 4) • MIR124-3 (MicroRNA 124-3)
    1m
    MicroRNAs in Prostate Cancer Liquid Biopsies: Early Detection, Prognosis, and Treatment Monitoring. (PubMed, Cells)
    Although promising, clinical implementation of miRNA-based assays requires further validation, standardization of protocols, and large-scale prospective studies. Harnessing circulating miRNAs could usher in a new era of precision oncology for PCa, improving early diagnosis, prognostication, and real-time therapeutic guidance.
    Review • Journal • Liquid biopsy
    |
    MIR200B (MicroRNA 200b) • MIR21 (MicroRNA 21) • MIR141 (MicroRNA 141) • MIR23b (MicroRNA 23b) • MIR375 (MicroRNA 375) • MIR20A (MicroRNA 20a) • MIR326 (MicroRNA 326)
    2ms
    INTEGRATED EXPRESSION PROFILE OF THE MMP-TIMP-MIRNA AXIS IN BREAST CANCER CELL LINES OF DIFFERENT MOLECULAR SUBTYPES. (PubMed, Exp Oncol)
    The study demonstrates that the MMP-TIMP-miRNA axis exhibits subtype-specific expression patterns in the BC cell lines. The observed heterogeneity highlights the importance of post-transcriptional regulation and suggests that integrated profiling of MMPs, TIMPs, and regulatory miRNAs may provide novel insights into the invasive potential of BC and identify candidate biomarkers for clinical validation.
    Preclinical • Journal
    |
    MIR155 (MicroRNA 155) • MIR200B (MicroRNA 200b) • MMP2 (Matrix metallopeptidase 2) • MIR34A (MicroRNA 34a-5p) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • TIMP2 (TIMP Metallopeptidase Inhibitor 2) • MIR100 (MicroRNA 100) • MMP9 (Matrix metallopeptidase 9) • MIR132 (MicroRNA 132) • MMP1 (Matrix metallopeptidase 1) • MIR145 (MicroRNA 145) • MMP8 (Matrix Metallopeptidase 8) • TIMP3 (TIMP Metallopeptidase Inhibitor 3)
    2ms
    miRNA as a Prognostic Marker in Small Lung Cell Carcinoma. (PubMed, Genes (Basel))
    In particular, strategies that restore or inhibit miRNA activity using mimics or antagomiRs show promise in improving drug sensitivity and complementing current treatment options. Overall, emerging evidence supports the integration of miRNA profiling into precision oncology for SCLC, with the aim of refining diagnosis, risk assessment and therapeutic decision-making.
    Review • Journal • PARP Biomarker
    |
    PARP1 (Poly(ADP-Ribose) Polymerase 1) • MIR200B (MicroRNA 200b) • TGFB1 (Transforming Growth Factor Beta 1) • MIR100 (MicroRNA 100) • MIR7 (MicroRNA 7) • MIR335 (MicroRNA 335) • MIR494 (MicroRNA 494) • MIR495 (MicroRNA 495) • MIR181B1 (MicroRNA 181b-1) • MIR22 (MicroRNA 22) • MIR30A (MicroRNA 30a) • MIR134 (MicroRNA 134)
    2ms
    Serum miRNA and Metabolomic Signatures of Residential Radon Exposure in Chiang Mai, Thailand. (PubMed, Toxics)
    Given the small sample size (n = 10), these findings should be interpreted as preliminary and hypothesis-generating, warranting validation in larger cohorts. Nevertheless, findings support household testing, remediation at ≥100 Bq/m3, and integrated exposure studies considering PM2.5 co-exposures.
    Journal • Metabolomic study
    |
    MIR200B (MicroRNA 200b) • MIR200C (MicroRNA 200c) • MIR584 (MicroRNA 584) • MIR125A (MicroRNA 125a) • MIR194 (MicroRNA 194) • MIR22 (MicroRNA 22) • MIR30A (MicroRNA 30a)
    3ms
    Stage- and smoking-associated microRNA expression in lung adenocarcinoma. (PubMed, Transl Lung Cancer Res)
    Among the miRNA alterations associated with stage I adenocarcinoma in nonsmokers, we found alterations in all 5 miR-200 family members (miR-200b, miR-200a, miR-141, miR-429, and miR-200c). Our identification of miRNA alterations associated with early-stage lung adenocarcinoma in nonsmokers, especially alterations in the miR-200 family, suggests that these miRNAs may play a unique role in the early stages of lung carcinogenesis and progression in nonsmokers and that they may be useful as markers for the early detection of lung cancer.
    Journal
    |
    MIR200B (MicroRNA 200b) • MIR200C (MicroRNA 200c) • MIR429 (MicroRNA 429) • MIR200A (MicroRNA 200a) • MIR141 (MicroRNA 141) • MIR200 (MicroRNA 200)
    3ms
    MiR-200b-3p is involved in colorectal cancer progression by targeting DDIT4. (PubMed, Cell Mol Biol (Noisy-le-grand))
    DDIT4 promotes CRC progression and is regulated by miR-200b-3p. Targeting the miR-200b-3p/DDIT4 axis may represent a novel therapeutic approach for CRC treatment.
    Journal
    |
    MIR200B (MicroRNA 200b) • DDIT4 (DNA Damage Inducible Transcript 4)
    3ms
    Dihydroartemisinin inhibits metastatic potential and cancer stemness by modulating the miR-200b-BMI-1/VEGF-A axis in ovarian cancer. (PubMed, Exp Mol Med)
    Here we demonstrated that dihydroartemisinin (DHA), a derivative of the antimalarial drug artemisinin, inhibits CSC characteristics, tumor neovascularization and resistance to carboplatin via a microRNA-dependent mechanism in ovarian cancer...Overall, DHA targets the miR-200b-BMI-1/VEGF-A axis to suppress cancer stemness and metastatic potential, highlighting its therapeutic promise in overcoming the limitations of standard chemotherapy for ovarian cancer. The clinical trial number for this study is not applicable.
    Journal
    |
    KDR (Kinase insert domain receptor) • MIR200B (MicroRNA 200b) • BMI1 (BMI1 proto-oncogene, polycomb ring finger)
    |
    carboplatin
    3ms
    MiRNome alterations drive the malignant transformation of endometriosis into endometriosis-correlated ovarian cancer. (PubMed, Sci Rep)
    Evaluation of miRNAs commonly deregulated between the three groups showed 14 shared upregulated miRNAs (miR-429, miR-425-5p, miR-200c-3p, miR-200c-5p, miR-200b-3p, miR-200a-3p, miR-183-5p, miR-182-5p, miR-141-5p, miR-141-3p, miR-96-5p, miR-93-5p, miR-10a-5p, miR-10a-3p) with a progressive increase in expression levels, from ovarian EMS to TL and ultimately to ECOC. The identified miRNA expression profiles associated with the progression from ovarian EMS, TL and ECOC provide valuable insights into the molecular progression from benign to malignant lesions and could represent potential biomarkers for the early detection of ECOC.
    Journal
    |
    MIR200B (MicroRNA 200b) • MIR200C (MicroRNA 200c) • MIR429 (MicroRNA 429) • MIR200A (MicroRNA 200a) • MIR96 (MicroRNA 96) • MIR141 (MicroRNA 141) • MIR182 (MicroRNA 182) • MIR425 (MicroRNA 425) • MIR183 (MicroRNA 183) • MIR93 (MicroRNA 93)
    3ms
    miRNA Signatures in Endometrial Cancer: Implications for Oncogenesis and Polymerase Epsilon (POLE) Mutation Status. (PubMed, Int J Mol Sci)
    Our findings reveal that EC is characterized by widespread miRNA deregulation, with a unique global down-regulation signature in POLE-mutated tumors. These results highlight the potential of miRNAs as complementary biomarkers for classification and potential targets in EC.
    Journal
    |
    TP53 (Tumor protein P53) • POLE (DNA Polymerase Epsilon) • MIR200B (MicroRNA 200b) • MIR200C (MicroRNA 200c) • MIR23A (MicroRNA 23a) • MIR181A1 (MicroRNA 181a-1)
    |
    TP53 mutation • POLE mutation